Clinical Trial Update: Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure

View source ↗

Summary

This clinical trial update describes early metabolic adaptations to SGLT2 inhibitors in heart failure and notes that enrollment is by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• SGLT2 inhibitors (SGLT2 inhibitor)

Snippet

Sponsor: University of Pennsylvania | Conditions: Heart Failure NYHA Class II, Heart Failure NYHA Class III | Status: ENROLLING_BY_INVITATION